<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089019</url>
  </required_header>
  <id_info>
    <org_study_id>18177</org_study_id>
    <secondary_id>J2G-MC-JZJZ</secondary_id>
    <nct_id>NCT05089019</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants</brief_title>
  <official_title>An Open-Label, Randomized Study to Evaluate the Bioequivalence of Selpercatinib Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the amount of selpercatinib that gets into the&#xD;
      blood stream and how long it takes the body to get rid of it, when given as different&#xD;
      formulations. The information about any adverse effects experienced will be collected and the&#xD;
      tolerability of selpercatinib will also be evaluated. The study may last up to 56 days&#xD;
      including the 28 days of screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2021</start_date>
  <completion_date type="Anticipated">June 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib</measure>
    <time_frame>Predose on Day 1 &amp; 15 through Day 14 &amp; 28</time_frame>
    <description>PK: Cmax of Selpercatinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib</measure>
    <time_frame>Predose on Day 1 &amp; 15 through Day 14 &amp; 28</time_frame>
    <description>PK: AUC[0-∞] of Selpercatinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib</measure>
    <time_frame>Predose on Day 1 &amp; 15 through Day 14 &amp; 28</time_frame>
    <description>PK: AUC[0-tlast] of Selpercatinib</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Selpercatinib (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selpercatinib given orally on days 1 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selpercatinib (Reference)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Selpercatinib given orally on days 1 and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selpercatinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Selpercatinib (Reference)</arm_group_label>
    <arm_group_label>Selpercatinib (Test)</arm_group_label>
    <other_name>LY3527723</other_name>
    <other_name>LOXO-292</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, and vital signs.&#xD;
&#xD;
          -  Participants who have clinical laboratory test results within the normal reference&#xD;
             range for the population or investigative site, or results with acceptable deviations&#xD;
             that are judged to be not clinically significant by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of allergic reactions to medications or food products&#xD;
&#xD;
          -  Have a clinically significant abnormality of blood pressure and/or pulse rate as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Clinically significant abnormalities on ECG as determined by the investigator or&#xD;
             prolongation of the QTcB or QTcF &gt;450 msec at screening&#xD;
&#xD;
          -  Have clinically significant active cardiovascular disease or history of myocardial&#xD;
             infarction within 6 months prior to the planned start of selpercatinib&#xD;
&#xD;
          -  Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal,&#xD;
             endocrine, hematological, or neurological disorders capable of significantly altering&#xD;
             the absorption, metabolism, or elimination of drugs; of constituting a risk when&#xD;
             taking the investigational product; or of interfering with the interpretation of data.&#xD;
             Appendectomy, splenectomy, and cholecystectomy are considered as acceptable&#xD;
&#xD;
          -  Use of H2 blockers, proton pump inhibitors, and other drugs that affect selpercatinib&#xD;
             exposure within 7 days of screening&#xD;
&#xD;
          -  Are intending to use over-the-counter or prescription medication, including dietary&#xD;
             supplements, within 14 days prior to dosing and until study discharge (apart from&#xD;
             occasional acetaminophen (≤2 g/24 hours), hormonal contraception, or hormone&#xD;
             replacement therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7147747777 ext. 1013</phone>
    </contact>
    <investigator>
      <last_name>Peter John Winkle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LabCorp CRU, Inc.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>386-366-6446</phone>
    </contact>
    <investigator>
      <last_name>Hugh A Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-647-9305</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle L Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LabCorp CRU, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>6084431471</phone>
    </contact>
    <investigator>
      <last_name>John Evan Blanchard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

